EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2025

  • ID: 4027751
  • Drug Pipelines
  • 61 pages
  • GlobalData
1 of 3
Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. These lipids include low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C). An individual is considered to have dyslipidemia when there is an observed elevation in LDL-C or TG, or a low concentration of HDL-C (Grundy and Barnett, 1990).

Abnormalities in serum lipids can be caused by a variety of factors: lifestyle (alcohol, smoking, obesity), medical conditions (type 2 diabetes, hypothyroidism, obstructive liver disease), drugs (corticosteroids, beta blockers, protease inhibitors), or genetic polymorphisms (NIH, 2002).

In 2015, there were 580,825,262 total prevalent cases of dyslipidemia in the 8MM. This is forecast to grow to 680,288,645 by 2025, at an Annual Growth Rate (AGR) of 1.71%. Urban China made up the majority of the total prevalent cases in the 8MM throughout the forecast period, and will also experience the highest growth from 274,741,284 total prevalent cases of dyslipidemia in 2015 to 348,184,445 cases by 2025, at an AGR of 2.67%.

The US is forecast to grow at an AGR of 1.34%, from 133,104,335 total prevalent cases of dyslipidemia in 2015 to 150,918,348 cases by 2025. In the 8MM, there were 317,925,626 diagnosed prevalent cases of dyslipidemia, which is forecast to grow to 370,440,489 by 2025.

The report “EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2025” provides an overview of the risk factors, comorbidities, and global trends for dyslipidemia in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of dyslipidemia-which are defined as elevated low-density lipoprotein cholesterol (LDL-C), high triglycerides (TG), or low levels of high-density lipoprotein cholesterol (HDL-C)-as well as the total prevalent cases of increased LDL-C, and very high TG, segmented by sex and age.

Additionally, the forecast provides the total prevalent cases of familial hypercholesterolemia (FH) and very high TG in these markets.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1.1 List of Tables

1.2 List of Figures

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global Trends

2.4 Forecast Methodology

2.4.1 Sources Used Tables

2.4.2 Forecast Assumptions and Methods

2.4.3 Sources Not Used

2.5 Epidemiological Forecast for Dyslipidemia (2015-2025)

2.5.1 Dyslipidemia

2.5.2 Familial Hypercholesterolemia

2.5.3 Increased Low-Density Lipoprotein Cholesterol

2.5.4 High Triglycerides

2.5.5 Very High Triglycerides

2.5.6 Low High-Density Lipoprotein Cholesterol

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 Limitations of the Analysis

2.6.3 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologists

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.3 About the Author

3.4 About EpiCast

3.5 Disclaimer

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Dyslipidemia

Table 2: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Dyslipidemia

Table 3: 8MM, Sources Used to Forecast the Total Prevalent Cases of FH

Table 4: 8MM, Sources Used to Forecast the Total Prevalent Cases of Increased LDL-C

Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of High TG

Table 6: 8MM, Sources Used to Forecast the Total Prevalent Cases of Low HDL-C

Table 7: 8MM, Total Prevalent Cases of Dyslipidemia, Ages =20 Years, Both Sexes, N, Selected Years 2015-2025

Table 8: 8MM, Diagnosed Prevalent Cases of Dyslipidemia, Ages =20 Years, Both Sexes, N, Selected Years 2015-2025

Table 9: 8MM, Total Prevalent Cases of Increased LDL-C, Ages =20 Years, Both Sexes, N, Selected Years, 2015-2025

Table 10: 8MM, Total Prevalent Cases of High TG, Ages =20 Years, Both Sexes, N, Selected Years, 2015-2025

Table 11: 8MM, Total Prevalent Cases of Very High TG, Ages =20 Years, Both Sexes, N, Selected Years, 2015-2025

Table 12: 8MM, Total Prevalent Cases of Low HDL-C, Ages =20 Years, Both Sexes, N, Selected Years 2015-2025

1.2 List of Figures

Figure 1: 8MM Total Prevalent Cases of Dyslipidemia, Ages =20 Years, Both Sexes, N, 2015-2025

Figure 2: 8MM Diagnosed Prevalent Cases of Dyslipidemia, Ages =20 Years, Both Sexes, N, 2015-2025

Figure 3: 8MM, Total Prevalent Cases of FH, Both Sexes, Ages =20 Years, N, 2015 and 2025

Figure 4: 8MM, Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages =20 Years, N, 2015 and 2025

Figure 5: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages =20 Years, N, 2015

Figure 6: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages =20 Years, 2015

Figure 7: 8MM, Age-Standardized Total Prevalence of Increased LDL-C, Both Sexes, Ages =20 Years, 2015

Figure 8: 8MM, Total Prevalent Cases of High TG, Both Sexes, Ages =20 Years, N, 2015-2025

Figure 9: 8MM, Sex-Specific Total Prevalent Cases of High TG, Both Sexes, Ages =20 Years, N, 2015

Figure 10: 8MM, Age-Specific Total Prevalent Cases of High TG, Both Sexes, Ages =20 Years, 2015

Figure 11: 8MM, Age-Standardized Total Prevalence of High TG, Both Sexes, Ages =20 Years, 2015

Figure 12: 8MM, Total Prevalent Cases of Very High TG, Both Sexes, Ages =20 Years, N, 2015-2025

Figure 13: 8MM, Total Prevalent Cases of Low HDL-C, Both Sexes, Ages =20 Years, N, 2015-2025

Figure 14: 8MM, Sex-Specific Total Prevalent Cases of Low HDL-C, Ages =20 Years, N, 2015

Figure 15: 8MM, Age-Specific Total Prevalent Cases of Low HDL-C, Both Sexes, Ages =20 Years, 2015

Figure 16: 8MM, Age-Standardized Total Prevalence of Low HDL-C, Both Sexes, Ages =20 Years, 2015
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll